These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34127019)

  • 1. The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration.
    Zhang C
    J Transl Med; 2021 Jun; 19(1):259. PubMed ID: 34127019
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
    Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico A; De Giglio A; Parisi C; Gelsomino F
    Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing Mutant KRAS, STK11, KEAP1 in NSCLC.
    Cancer Discov; 2022 Oct; 12(10):2226. PubMed ID: 35997519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.
    Sumii M; Namba M; Tokumo K; Yamauchi M; Okamoto W; Hattori N; Sugiyama K
    Intern Med; 2023 Oct; 62(20):3001-3004. PubMed ID: 36858519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level.
    Bazhenova L
    Ann Oncol; 2023 Apr; 34(4):327-332. PubMed ID: 37061249
    [No Abstract]   [Full Text] [Related]  

  • 7. XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy.
    Li X; Zou B; Wang S; Wang L; Yu J
    J Transl Med; 2021 Oct; 19(1):421. PubMed ID: 34627293
    [No Abstract]   [Full Text] [Related]  

  • 8. Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
    Ricciuti B; Garassino MC
    J Thorac Oncol; 2024 Jun; 19(6):877-882. PubMed ID: 38849167
    [No Abstract]   [Full Text] [Related]  

  • 9. Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.
    Chen H; Zhang T; Zhang Y; Wu H; Fang Z; Liu Y; Chen Y; Wang Z; Jia S; Ji X; Shang L; Du F; Liu J; Lu M; Chong W
    JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35511432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.
    Dziadziuszko R
    J Thorac Oncol; 2022 Mar; 17(3):351-352. PubMed ID: 35216730
    [No Abstract]   [Full Text] [Related]  

  • 12. Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases.
    Xu Y; Huang Z; Yu X; Chen K; Fan Y
    Mol Brain; 2021 Dec; 14(1):176. PubMed ID: 34952628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.
    Rakaee M; Andersen S; Giannikou K; Paulsen EE; Kilvaer TK; Busund LR; Berg T; Richardsen E; Lombardi AP; Adib E; Pedersen MI; Tafavvoghi M; Wahl SGF; Petersen RH; Bondgaard AL; Yde CW; Baudet C; Licht P; Lund-Iversen M; Grønberg BH; Fjellbirkeland L; Helland Å; Pøhl M; Kwiatkowski DJ; Donnem T
    Ann Oncol; 2023 Jul; 34(7):578-588. PubMed ID: 37100205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 15. In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment?
    Kus T; Aktas G
    J Thorac Oncol; 2023 Aug; 18(8):e83-e84. PubMed ID: 37479333
    [No Abstract]   [Full Text] [Related]  

  • 16. A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
    Hijazo-Pechero S; Muñoz-Pinedo C; Nadal E
    J Thorac Oncol; 2023 Nov; 18(11):1431-1433. PubMed ID: 37879763
    [No Abstract]   [Full Text] [Related]  

  • 17.
    Papillon-Cavanagh S; Doshi P; Dobrin R; Szustakowski J; Walsh AM
    ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32312757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Kus T; Aktas G
    J Thorac Oncol; 2022 Jun; 17(6):e63-e64. PubMed ID: 35623683
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
    Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.